Comments
Pharmaceutical and life sciences company Jubilant Life Sciences is to raise debt up to $250 million (around Rs 1,353 crore). The issue will help the company pre-pay existing debt.
As of July last year, the company had Rs 3,675 crore debt. The company offers custom research and manufacturing services and drug discovery and development solutions globally.
The issue is to be made by way of foreign currency convertible bonds and non-convertible debentures, or a combination of the two, the company said in a filing to the stock exchange.
Q4 net dives
On May 8, Jubilant Life Sciences' announced its consolidated profit after tax (PAT), excluding extraordinary items, declined 20.48 per cent to Rs 66 crore in the fourth quarter of March 2013 over the fourth quarter of March 2012.
Income from operations rose 18 per cent to Rs 1,392 crore in the same period. EBITDA stood at Rs 244 crore in the same period.
Consolidated PAT, excluding extraordinary items, rose five per cent to Rs 382 crore in FY2013 over FY2012.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.